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A B S T R A C T
Lipoxins (LX) and 15-epi-LX are lipids with a potent inhibitory effect on angiogenesis, in different models
in vivo and in vitro. ATL-1, a synthetic analog of 15-epi-LXA4, inhibits various actions stimulated by
vascular endothelial growth factor (VEGF). However, LX actions on endothelial cells (EC) in tumor-
related contexts are still unknown. Here, we investigated the modulation of EC by ATL-1, in a model that
mimics tumor extravasation. We observed that the analog inhibited endothelial permeability induced by
VEGF, through the stabilization of VE-cadherin/b-catenin-dependent adherens junctions. We tested the
ability of MV3 cells, a highly metastatic melanoma cell line, to transmigrate across unchallenged EC
monolayers for 18 h, as compared to NGM normal melanocytes. ATL-1 was able to inhibit only
melanoma extravasation. MV3 cells secrete large amounts of VEGF and we observed that ATL-1 per se did
not alter this ability. Melanoma cells skills to crossing endothelial monolayers were due to the steady
accumulation of tumor-derived VEGF. When endothelial cells were challenged with exogenous VEGF,
added at levels comparable to those secreted by MV3 cells over 18 h, and a short-term (4 h)
transendothelial migration assay was performed, both melanoma and melanocyte cells were able to
extravasate, and ATL-1 was able to block the passage of both cells. These results indicate that ATL-1 has a
potent inhibitory effect on the permeability induced by VEGF, and that this pharmacological effect could
be used to block tumor extravasation across endothelial barriers, with a possible prospect of reducing the
haematogenic spread of cancer cells.
 2014 Elsevier Inc. All rights reserved.
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Malignant tumors arise from genetic, epigenetic and microen-
vironmental alterations that might eventually culminate with the
fostering of fast growing cell masses, not rarely primed for invasion
of tissues and even of distant organs [1]. Metastasis is a multi-step
process that includes transendothelial tumor cell migration,
intravasation of cancer cells into vessels, followed by hematoge-
nous extravasation and the settlement of new tumor cells at* Corresponding author at: Departamento de Biologia Celular/IBRAG, Laborato´rio
de Biologia da Ce´lula Endotelial e da Angiogeˆnese (LabAngio), Rua Sa˜o Francisco
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0006-2952/ 2014 Elsevier Inc. All rights reserved.secondary sites [2]. Recent studies have shown that tumor growth
and metastasis are strongly inﬂuenced by a variety of cues
provided by stromal cells such as ﬁbroblasts, immune system cells,
and endothelial cells (EC), which create a supportive microenvi-
ronment for tumor progression [3–5].
Blood vessel walls form a selective barrier for the transport of
molecules between blood and tissues, and vascular health is
largely kept by endothelial integrity [6]. The endothelium is a
continuous monolayer formed by cells linked to each other by
different types of cell-to-cell junctions. These complex structures
are formed by transmembrane adhesive molecules linked to a
network of cytoskeletal proteins. On the basis of morphological
and functional characterization, three types of junctions have been
described in endothelial cells [7,8] tight junctions, adherens
junctions, and gap junctions. Adherens junctions are formed by
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cell surface. Cadherins are cell adhesion molecules, which are
anchored with their cytoplasmic tail to a network of intracellular
cytoplasmic proteins such as catenins, which are connected to the
actin-based microﬁlament system [9]. Endothelial permeability
changes are associated with redistribution of surface cadherins
and stabilization of focal adhesion bonds [10]. Loss of barrier
properties in pathophysiological situations can lead to extracellu-
lar edema.
Many tumors express high levels of the proangiogenic factor
VEGF [11]. VEGF exerts its effects mainly by binding two speciﬁc
tyrosine kinase receptors, VEGFR-1 (also named Flt-1) and VEGFR-2
(KDR/Flk-1). Signaling through endothelial VEGFR-1 in angiogenesis
remains an elusive question, since the tyrosine kinase activity of this
receptor is poor and not required for endothelial cell function [12].
However, a role of both membrane-bound and soluble VEGFR-1 as
negative modulators of angiogenesis has been proposed in the last
years, an activity centrally based on the very high afﬁnity of this
receptor for VEGF, which would render this growth factor less
available for binding to VEGFR-2. This property would be responsi-
ble for keeping adequate rates of angiogenesis and vasculogenesis
during development and also in normal homeostasis, and would
explain why mice embryos bearing vegfr1/ genotypes undergo
early embryonic death, a failure linked to excessive formation of
disorganized lumen-less vessels [13].
VEGFR-2 plays a central role in angiogenesis and permeability
of EC [14]. Once activated, VEGFR-2 dimerizes and becomes
autophosphorylated, leading to the phosphorylation of several
cytoplasmic signaling molecules. VEGF has been reported to
induce VE-cadherin phosphorylation, thus initiating the loosening
of adherens junctions [15]. VEGF165 and VEGF189 are splicing
variants of the VEGF-A isoform, and both constitute the most
potent inductors of vascular permeability within this growth factor
family [16].
The practical possibility of controlling vascular permeability
has several therapeutic implications. For example, vascular leakage
in tumors not only facilitates metastatic dissemination, but also
contributes to the elevated interstitial pressure that is a trait
shared by several solid tumors [17]. Elevated interstitial pressure is
probably the cause of altered tumor perfusion and impaired drug
delivery. Conversely, decreasing vascular permeability might be
beneﬁcial because it might increase drug accessibility to tissues.
Non-steroidal anti-inﬂammatory drugs, such as aspirin (ASA),
have been suggested to prevent certain types of cancer, such as lung,
colon, and breast cancers, and its mechanism of action is thought to
result from antiangiogenic activity [18,19]. ASAs therapeutic
mechanism of action includes the inhibition of COX-2-derived
prostanoids [20]. In addition, when acetylated by ASA, COX-2 ability
to generate prostanoids is blocked, but remains active in EC to induce
the biosynthesis of ASA triggered-15-epi-lipoxin A4 (ATL) [21]. These
endogenous lipid mediators are the carbon 15 epimers of the native
lipoxins (LX) and mimic some of their bioactivities [22]. ATL can be
generated in vivo during cell–cell interactions, such as EC–
neutrophil interaction [23] and display potent inhibitory actions
in several key events in inﬂammation [24].
Our group has reported diverse effects of 15-epi-16-(paraf-
luoro)- phenoxy-lipoxin A4 (ATL-1) on endothelial cells. We
demonstrated that ATL-1 inhibited VEGF-stimulated endothelial
migration, an essential component of the angiogenic process, in a
concentration-dependent manner [25,26]. Furthermore, ATL-1
modulates essential components of the motile process, by
impairing actin polymerization and focal adhesion assembly [27].
Here, we demonstrated that ATL-1 inhibits VEGF-induced
endothelial permeability, leading to an important impairment of
the transendothelial migration capacity of a highly invasive human
melanoma cell line. These effects were directly related to theintegrity of VE-cadherin-mediated junctions. Besides the well
described anti-angiogenic properties of ATL-1 [25–28], the new
data presented herein are supportive of the therapeutic potential
of lipoxin synthetic analogs also as anti-metastatic drugs, through
the targeting of the extravasation of tumor cells across endothelial
barriers.
2. Materials and methods
2.1. Antibodies and other reagents
Polyclonal rabbit anti-VE-cadherin [pY658] antibody, and FITC-
or Alexa Fluor1 455- streptavidin conjugates were purchased from
Life Technologies (Brazilian division, Sa˜o Paulo, Brazil). Goat anti-
histone H3 and anti-VE-cadherin, and rabbit anti-b-catenin
antibody were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Biotin-labeled anti-IgG antibody was obtained from
Abcam (Cambridge, UK). VEGF-A165 isoform (referred as VEGF in
this paper) was obtained from R&D Systems (Minneapolis, MN,
USA). Fetal calf serum (FCS) was purchased from Cultilab
(Campinas, SP, Brasil). HEPES, trypsin, EDTA, bovine serum
albumin (BSA), PMSF, benzamidine, leupeptin, soybean trypsin
inhibitor, ﬂuorescein isothiocyanate-dextran (dextran-FITC, aver-
age MW 40,000) and vital PKH26 red ﬂuorescent dye for cell
membrane labeling (PKH26GL-1KT) were from Sigma–Aldrich (St.
Louis, MO, USA). General supplies for buffers and saline solutions,
detergents and protease and phosphatase inhibitors were obtained
from Sigma–Aldrich (St. Louis, MO, USA). Unless otherwise stated,
all reagents for cell culture were purchased from Life Technologies
(Brazilian Division, Sa˜o Paulo, Brazil).
2.2. Cell culture
Primary endothelial cells were isolated from human umbilical
vein (HUVEC) as previously described [29]. Umbilical cords were
collected according to the guidelines provided by SISNEP/CONEP –
Brazilian Ministry of Health (CAAE: 0086.0.314.325-10 – Source
Protocol #74/2010, approved by the SMSDC-RJ/City of Rio Janeiro
Research Ethics Committee). At least ﬁve independent primary
cultures were pooled for each experiment, in order to minimize the
interference of individual genetic variation. The human melano-
cyte cell line (NGM) was obtained from Cell Bank of Rio de Janeiro
(RJ, Brazil). The human melanoma strain (MV3) with high
metastatic potential [30], was kindly donated by Dr. Cezary
Marcienkevickz, (Temple University, PA, USA). The immortalized
human microvascular endothelial cell line (HMEC-1) [31] was
kindly provided by Dr. Francisco Candal (Emory School of Medicine
& CDC, Atlanta, GA, USA). HUVECs were cultured in medium 199
containing 20% FCS, 50 U/mL penicillin, 15 mg/mL streptomycin,
8 U/mL heparin, and 6 g/L HEPES. MV3 and NGM were cultured in
DMEM supplemented with 10% FCS, 100 U/mL penicillin, and
100 mg/mL streptomycin. HMEC-1 was cultured in MCDB-131
culture medium (Sigma–Aldrich) supplemented with 14 mM
NaHCO3, 15 mM HEPES, 0.5 U/mL penicillin, 0.5 mg/mL strepto-
mycin, 1 mg/mL hydrocortisone, 10 ng/mL EGF (Sigma, St Louis,
MO, USA) and 10% FBS. The cultures were incubated at 37 8C in
humidiﬁed 5% CO2 atmosphere. The medium was changed every
24–48 h and the cells were passaged at conﬂuence, after
dissociation with 0.1%/0.01% trypsin/EDTA.
2.3. Preparation of cell extracts
Endothelial cells were treated with ATL-1 and then stimulated
with VEGF. To obtain whole-cell extracts, 106 cells were
resuspended in lysis buffer (50 mM HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulphonic acid, pH 6.4, containing 1 mM
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with the following protease inhibitors: 1 mM phenylmethylsulfo-
nyl ﬂuoride (PMSF), 1 mM benzamidine, 1 mM aprotinin, 1 mM
leupeptin and 1 mM soybean trypsin inhibitor.
2.4. VEGF quantiﬁcation by ELISA
To investigate the rate of VEGF secretion, HUVECs, NGM and
MV3 cells (2  105) were grown in medium supplemented with
0.1% bovine serum albumin (BSA) for 4, 8, 16 or 24 h. Collected
conditioned media samples were stored at 80 8C. We also
prepared samples from MV3 cells treated with ATL-1 (100 nM) and
then incubated for 4 or 18 h at 37 8C in humidiﬁed 5% CO2
atmosphere. VEGF levels in tumor conditioned media were
determined by using the standard ELISA Development Kit from
Peprotech (Rocky Hill, NJ, USA), according to the manufacturer’s
instructions.
2.5. Tumor transendothelial migration assay
HUVECs (5  104 cells) were plated on 8.0 mm-pore BD Falcon
Cell Culture inserts (to ﬁt inside standard 24-well culture plates).
Cells were pretreated or not with ATL-1 (100 nM) and stimulated
or not with VEGF (10 ng/mL) for 1 h. After the treating medium was
removed, PKH126-labeled MV3 melanoma cells (3  104) were
allowed to migrate across endothelial monolayers for 4 or 18 h. The
bottom side of each insert was ﬁxed in 3.7% formaldehyde in PBS
and the upper side was cleaned with a ﬂexible rod. The labeled cells
in at least 10 ﬁelds per insert were counted on a ﬂuorescence
microscope (model IX-71, Olympus, Tokyo, Japan).
2.6. Endothelial permeability assay
To determine endothelial monolayer permeability, we used a
standard Dextran-FITC protocol and an endothelial cell line of
microvascular origin (HMEC-1 cells) which in our hands generated
the lowest thresholds for 40,000 dextran-FITC detection (observa-
tions from previous protocol optimizations; not shown). HMEC-1
(5  104 cells) were plated on Falcon Cell Culture Inserts (0.4 mm-
pore size, to ﬁt inside standard 24-well culture plates). Cells were
pretreated with ATL-1 (100 nM) and stimulated or not with VEGF
(100 ng/mL) for 1 h. To detect changes in monolayer permeability,
500 mL assay medium without phenol red was added to each lower
chamber and 150 mL assay medium without phenol red containing
Dextran-FITC (1 mg/mL) was added on the top of each insert.
HMEC-1 monolayer permeability was quantiﬁed as clearance of
Dextran-FITC from the upper chamber to the lower one, the
ﬂuorescent content was measured using Wallac EnVision 2104
Multilabel Reader (Perkin-Elmer, Waltham, MA, USA) at 490 nm
and 535 nm absorption/emission wavelengths.
2.7. Preparation of nuclear extracts
Cells were treated with ATL-1 and stimulated with VEGF for 4 h.
Intranuclear proteins were obtained by lysing the cells with 10 mM
HEPES, pH 7.9, containing 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA
(ethylene glycol bis (b-aminoethylether)-N,N,N0,N0,-tetraacetic
acid), 1 mM DTT (dithiothreitol), aprotinin (10 mg/mL), leupeptin
(10 mg/mL), pepstatin (2 mg/mL) and 1 mM PMSF for 15 min at
4 8C. NP40 (Nonidet P40) (5%) was next added and the nucleus was
pelleted at 12,000  g for 5 min at 4 8C. The pellet was resuspended
in 20 mM HEPES, pH 7.9, containing 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, aprotinin (10 mg/mL), leupeptin (10 mg/mL),
pepstatin (2 mg/mL) and 1 mM PMSF, and then it was incubated at
4 8C for 30 min. The whole lysate was centrifuged at 12,000  g for
10 min at 4 8C. Only supernatants were used. The total amount ofproteins in lysates was measured by the BCA kit (Pierce
Biotechnology, Inc., Rockford, IL, USA).
2.8. Western blots
Cell lysates were denatured in sample buffer (50 mM Tris–HCl,
pH 6.8, 1% sodium dodecyl sulphate, 5% b-mercaptoethanol, 10%
glycerol, 0.001% bromophenol blue) and heated in a boiling water
bath for 5 min. Samples were resolved by SDS-PAGE and proteins
were transferred to PVDF membranes (Millipore Corp., Sa˜o Paulo,
Brazil). Rainbow-colored protein molecular weight markers (GE
Healthcare Life Sciences, Sa˜o Paulo, Brazil) were run in parallel to
estimate molecular weights. Then, membranes were blocked for
30 min with 5% BSA in Tris-buffered saline (TBS-T) (20 nM Tris, pH
7.6, containing 0.8% NaCl and 0.1% Tween 20) and probed overnight
with speciﬁc antibodies at 4 8C. The membranes were incubated
with either anti-VE cadherin (1:500), or anti-phospho VE-cadherin
(Y658, 1:1000) or anti-b catenin (1:500), or anti-histone H3 (1:
1000) primary antibodies. After washing steps with TBS-T,
membranes were incubated with biotin-conjugated anti-IgG
antibody for 1 h, washed again and then incubated with
streptavidin-conjugated horseradish peroxidase. Bound antibodies
were detected by enhanced chemiluminescence (ECL, Pierce,
Rockford, IL, USA). The bands were quantiﬁed by densitometry,
using Image J Software (Scion Co., Frederick, MD, USA).
2.9. Immunoﬂuorescence microscopy
Endothelial cells grown to conﬂuence on 13 mm diameter
coverslips, previously covered with gelatin 2% were treated with
ATL-1 and stimulated with VEGF for 4 h at 37 8C. The monolayers
were washed twice with PBS. Cells were then ﬁxed with 4%
paraformaldehyde/4% sucrose in PBS for 20 min and blocked with
5% BSA in PBS for 30 min. The cells were then incubated with anti-
VE-cadherin or anti-b-catenin Ab (1:400) overnight at 4 8C.
Subsequently, the cells were washed three times with PBS and
incubated with biotin-conjugated anti-IgG (1:400), followed by
incubation with FITC- or Alexa Fluor1 455-conjugated streptavidin
(1:400) for 1 h at room temperature. Cells were covered with 4,6-
diamidino-2-phenylindole for 1 min and washed three times with
PBS. Coverslips were mounted on a slide with the use of a 20 mM
N-propylgalate and 80% glycerol solution in PBS before examina-
tion under an microscope (model IX-71 Olympus, Tokyo, Japan)
equipped for epiﬂuorescence. The images were analyzed using
Photoshop software (Adobe Systems, San Jose, CA).
2.10. Statistical analysis
Statistical signiﬁcance was assessed by ANOVA, followed by
Bonferroni’s t-test, and P < 0.05 was taken as statistically
signiﬁcant.
3. Results
3.1. ATL-1 inhibits VEGF-induced endothelial permeability by
stabilizing VE-cadherin-dependent junctions
We ﬁrst decided to investigate whether ATL-1 could reduce the
endothelial permeability stimulated by VEGF. Microvascular
HMEC-1 cells, which usually generate more sensible thresholds
for the detection of labeled macromolecule tracers for permeability
assessments, were plated into porous inserts and then pretreated
or not with ATL-1 (100 nM) for 30 min before the incubation with
VEGF (100 ng/mL). As expected, the stimulation of endothelial cells
with VEGF increased Dextran-FITC (MW = 40,000) passage through
the endothelial monolayer (Fig. 1). The pre-treatment with ATL-1
Fig. 1. ATL-1 inhibits VEGF-induced permeability. Dermal microvascular HMEC-1
cells (5  104) were grown on porous inserts (0.4 mm porosity) and pre-treated or
not with ATL-1 (100 nM) for 30 min, before incubation with (100 ng/mL) or without
VEGF for 1 h, in medium containing dextran-FITC (1 mg/mL). The ﬂuorescence
density was quantiﬁed using a plate reader (EnVisionTM) at an excitation
wavelength of 485 nm and an emission wavelength of 535 nm. Results represent
mean and standard deviation of three similar and independent experiments.
*P < 0.05 refers to the value obtained for VEGF treatment versus all other groups.
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ATL-1 had no direct effect on endothelial permeability.
To determine if ATL-1 could impair AJ disruption, we pre-
incubated HUVECs with ATL-1 (100 nM) for 30 min and then with
VEGF (100 ng/mL), before visualizing VE-cadherin distribution by
immunoﬂuorescence analysis (Fig. 2). We observed a strong
pericellular staining of VE-cadherin in cells that were not treated
with VEGF, and also in cells incubated with ATL-1 alone (Fig. 2A).
By contrast, HUVECs stimulated with VEGF exhibited large
portions of disrupted pericelullar VE-cadherin staining. This effect
was completely precluded when the pretreatment with ATL-1 was
performed.
We next analyzed whether ATL-1 effect on VE-cadherin-
dependent junctions was related to the inhibition of VE-cadherin
phosphorylation induced by VEGF. As shown in Fig. 2B, ATL-1 was
able to impair VEGF-induced VE-cadherin phosphorylation on
tyrosine 658 (Y658).
3.2. ATL-1 prevents the VEGF-induced nuclear translocation of b-
catenin
When HUVECs were treated with ATL-1 (100 nM) for 30 min
before incubation for 4 h with VEGF, we observed a mostly
continuous staining of b-catenin in the pericellular region (Fig. 3).
By contrast, in the absence of ATL-1, VEGF treatment led to a
reduction of the pericellular staining of the protein, with a
signiﬁcant loss of the continuous surface staining, a pattern
consistent with a possible redistribution of b-catenin toward
intracellular compartments. In fact, the comparative analysis of
nuclear pools of b-catenin by western blotting (Fig. 4) demon-
strated that the pre-treatment of endothelial cells with ATL-1
prevented VEGF-induced nuclear translocation of b-catenin.
3.3. ATL-1 reduces transendothelial migration of MV3 melanoma cells
but not the migration of normal melanocytes: a role for tumor derived-
VEGF
We then decided to evaluate the effect of ATL-1 on the ability of
MV3 cells, an invasive human melanoma cell line, to transmigrate
across an endothelial barrier, as compared to a normal melanocyte
cell line counterpart, NGM cells. For this purpose, HUVECs grown
to conﬂuence on porous inserts were pretreated or not with ATL-1
(100 nM) for 30 min. After treatments, NGM or MV3 cells wereincubated with the endothelial monolayer for an additional 18 h.
As shown in Fig. 5, the total number of MV3 migrating cells was
about 3-fold over the number of migrating NGM melanocyte cells.
MV3 cells treated with ATL-1 showed a signiﬁcant decrease in the
migration as compared to untreated groups (control) or vehicle
(ethanol) (Fig. 5A). However, ATL-1 per se had no effect on the
transendothelial migration of NGM cells (Fig. 5B).
We next decided to evaluate the endogenous production of
VEGF by MV3 melanoma cells and to elucidate if ATL-1 could
interfere with this secretion. Using a quantitative ELISA assay, we
demonstrated that MV3 melanoma cells continuously secrete large
amounts of VEGF in culture (Fig. 6A). VEGF secreted by MV3
melanoma cells varied from pg/mL concentrations in the ﬁrst
hours of secretion, to ng/mL amounts after 24 h (2 ng/mL/
2  105 cells). By contrast, NGM melanocytes secreted extremely
low basal levels of this angiogenic factor. In fact, even the amounts
detected after 16 or 24 h in NGM cells conditioned media were
barely statistically signiﬁcant (Fig. 6A). The secretion of VEGF by
HUVECs was not detectable by this procedure. Additionally, the
pre-treatment of MV3 cells with ATL-1 (100 nM) had no effect on
the short-term (4 h) and long-term (18 h) secretion of VEGF
(Fig. 6B), indicating that the inhibitory effect of ATL-1 on
melanoma transendothelial migration was not due to a direct
interference on the ability of MV3 cells to secrete VEGF, and that
the large endogenous production of VEGF by melanoma cells was
probably sufﬁcient to trigger endothelial permeability along the
18 h period used in the transmigration assay.
In order to ultimately demonstrate the effect of ATL-1 as an
antagonist of endothelial permeability to tumor cells, we decided
to directly stimulate endothelial monolayers with exogenously
added VEGF (10 ng/mL), but now performing a short-term
transendothelial tumor migration assay of 4 h. (Fig. 7). Effectively,
in the presence of exogenous VEGF added at ng/mL levels, MV3
melanoma cells transmigrated in levels that were comparable to
those observed in the long-term assay (18 h), previously ran in the
absence of exogenously added growth factor. The pre-treatment of
HUVECs with ATL-1 impaired the VEGF-induced transmigration of
MV3 cells (Fig. 7A). On the other hand, the treatment of endothelial
cells with VEGF led to a signiﬁcant higher number of NGM
melanocytes to transmigrate across endothelial monolayers after
4 h (Fig. 7B), as compared to the rates observed after 18 h (Fig. 5B),
although the rates remain very low when compared with the
malign cell line. Importantly, ATL-1 was able to partially abrogate
NGM cells migration in this short-term VEGF-induced migration
assay. These data clearly indicate that the ability to secrete
elevated amounts of VEGF is rate-limiting to the process of cell
extravasation across endothelial barriers, and also conﬁrms that
VEGF-activated pathways represent crucial targets to ATL-1
pharmacological activity.
4. Discussion
The contemporary view deﬁnes cancer as tissues that would not
only consist of transformed cells with excessive proliferation, but
that also contain other cells and molecules able to interact,
regulate and modify the behavior of tumor cells [3–5,32,33].
Vascularization is essential for the development of cancer,
ensuring perfusion and sustainment of the whole tumor microen-
vironment [34]. Endothelial cells are the ﬁrst in contact with any
element present in the blood and are especially prevalent in malign
tumors [35].
Besides, there are also strong evidences of a close association
between inﬂammation and angiogenesis in various human
diseases, including cancer [1,36]. Understanding the inﬂamma-
tory pathways involved in cancer is expected to help in the
development of new anti-cancer therapies. Lipoxins, ATL and its
Fig. 2. ATL-1 inhibits VEGF-induced permeability by stabilizing of VE-cadherin-dependent junctions. (A) HUVEC (2  105) were grown in 24 well plates and treated or not
with ATL-1 (100 nM) for 30 min prior to incubation with VEGF (10 ng/mL) or not for 1 h. Cells were immunostained with anti-VE-cadherin and nuclei were labeled with DAPI.
Magniﬁcation: 60. Images are representative of three similar experiments. (B) HUVEC (1  106) were grown in 6-well plates and treated or not with ATL-1 (100 nM) for
30 min before the incubation with or without VEGF (10 ng/mL) for 10 min. The total extract was obtained and analyzed by western blotting using speciﬁc antibodies against
phosphorylated VE-cadherin (Y658) and VE-cadherin. The bands were analyzed by densitometry. Values represent mean and standard deviation of three similar and
independent experiments, and a representative blot is showed, for illustration purposes. *P < 0.05 refers to the value obtained for VEGF treatment versus control, and
#P < 0.05 refer to ATL-1 + VEGF versus VEGF.
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the anti-inﬂammatory and pro-resolution actions [37], have
anti-angiogenic actions [26–28,38]. Here, we exploited the
potential of ATL-1, a synthetic ATL analog, as a modulator of
VEGF-induced vascular permeability, and its ability to modulate
tumor cells transendothelial migration.
Tumor vessels are characterized by increased permeability,
which is expected to facilitate the inﬁltration of tumor cells toward
secondary sites [39]. In endothelial cells, it has been shown thatsoluble factors such as histamine, thrombin and VEGF increase
vascular permeability, by affecting tyrosine phosphorylation of
several components of the VE-cadherin/catenin complex
[14,31,40,41]. The activation of VEGFR-2 by VEGF leads to VE-
cadherin phosphorylation, which has been correlated with the
relaxation of cadherin-mediated adhesion in many cell types
[33,42–45]. The activation of VEGFR-2/Kdr receptor results in
rearrangement and turnover of VE-cadherin and b-catenin on the
cell membrane [14,31,46]. Our group demonstrated that ATL-1 is a
Fig. 3. ATL-1 modulates b-catenin translocation to cell nucleus. HUVEC (2  105) were grown in 24 well plates and treated or not with ATL-1 (100 nM) for 30 min before the
incubation with or without VEGF (10 ng/mL) for 4 h. Cells were incubated with an anti-b-catenin antibody and revealed in green ﬂuorescence, as described in Section 2, and
nuclei were labeled with DAPI. The cells were viewed with a ﬂuorescence microscope. Magniﬁcation: 60. Images are representative of three similar experiments.
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[26]. Here, we demonstrated that ATL-1 was able to impair the
permeability-inducing activity of VEGF, by stabilizing AJs at the
pericellular region.
A crucial mechanism underlying the VEGF-dependent loosen-
ing of AJs is the dissociation of b-catenin from the cytoplasmic tail
of VE-cadherin [47,48]. When b-catenin is dissociated fromFig. 4. ATL-1 inhibits VEGF-induced nuclear translocation of b-catenin. HUVEC
(1  106) were cultured in 6 well plates and treated or not with ATL-1 (100 nM) for
30 min before the incubation with or without VEGF (10 ng/mL) for 4 h. The nuclear
extract was obtained and analyzed by western blot using speciﬁc antibodies against
b-catenin and histone H3. The blots were analyzed by densitometry. Values
represent mean and standard deviation of three similar and independent
experiments. *P < 0.05 refers to the value obtained for VEGF treatment versus all
other groups.VE-cadherin, it may take different pathways: b-catenin may be
phosphorylated and degraded quickly in the cytoplasm [49] or,
in certain conditions, the non-phosphorylated b-catenin may
initially accumulate in the cytoplasm and later translocate to the
nucleus, where it can trigger the activation of several transcription
factors involved in the regulation of migration and proliferation of
endothelial cells [50].
Several sites for tyrosine phosphorylation have been identiﬁed
on the cytosolic portion of VE-cadherin so far [51]. Phosphorylation
of Y658, Y731 [52] and Y685 [53] leads to inhibition of cell barrier
function, in a process that largely depends on the activation of Src
family kinases [52–54]. In the present work, we showed that ATL-1
inhibits VEGF-induced phosphorylation of VE-cadherin on Y658.
Besides, we showed that the pre-treatment of endothelial cells
precluded the translocation of b-catenin translocation to the
nucleus after cell treatment with VEGF. We suggest that ATL-1
might favor b-catenin retention at AJ complexes, thus leading to
the strengthening of endothelial junctions.
We have previously shown that ATL-1 anti-angiogenic effects
on endothelial cells were antagonized by sodium orthovanadate
and correlated with SHP-1 phosphatase association with VEGFR-2
[26]. A number of other phosphatases such as VE-PTP, PTP1B, PTPm
and SHP-2, are also known to associate with VE-cadherin and
control its level of phosphorylation [55]. Therefore, although we
hypothesize that ATL-1 primarily interferes with the most
upstream component of VEGF-induced signaling pathway –
namely, the phosphorylation of the tyrosine kinase receptor
VEGFR-2 – the possibility that this analog could also affect
phosphatases acting on VE-cadherin cytoplasmic tail deserves
further investigation.
Recently, it has been demonstrated that endothelial FAK (focal
adhesion kinase) directly phosphorylates VE-cadherin on tyrosine
Y658 in response to cell activation by VEGF; conversely, the
Fig. 5. ATL-1 inhibits long-term (18 h) tumor transendothelial migration in the absence of exogenously added VEGF. HUVEC (5  104) were grown to conﬂuence onto porous
inserts (8 mm) and then pretreated or not with ATL-1 (100 nM) or EtOH (vehicle) for 30 min. After the treatment, MV3 melanoma cells (3  104) (A) or NGM melanocytes
(3  104) (B) previously labeled with PKH126 vital ﬂuorescent dye were incubated with endothelial monolayers for 18 h. Cells were counted in a ﬂuorescence microscope.
Values represent mean and standard deviation of three similar and independent experiments. *P < 0.05, when compared to control and EtOH groups.
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[56]. Interestingly, we have previously shown that ATL-1 inhibited
VEGF-stimulated migration of endothelial cells, by blocking focal
adhesion clustering, due to the inhibition of FAK phosphorylation.
Thus, the effect of ATL-1 in preserving the barrier properties ofFig. 6. VEGF quantiﬁcation in cell conditioned media. (A) Conditioned media
collected from HUVEC, NGM and MV3 cells (2  105) at different times (4, 8, 16 and
24 h) were analyzed using ELISA. Values represent mean and standard deviation of
3 similar and independent experiments. *P < 0.05 as compared with HUVEC, NGM
and the times 4 and 8 h of MV3. (B) MV3 cells (1  106) were cultured in 6 well
plates and treated or not with ATL-1 (100 nM) or EtOH (vehicle) for 4 or 18 h.
Conditioned medium was collected and analyzed using ELISA. Results represent
mean and standard deviation of three similar and independent experiments.vascular endothelial cells in vitro could also result from its ability to
inhibit endothelial FAK.
A number of different molecules have been described as potent
activators of vascular permeability, and also identiﬁed as tumor-
secreted factors [reviewed by [57]]. Among these, the secretion of
large amounts of different VEGF isoforms appears as a hallmark of
malign cancers. Increased VEGF expression occurs in malignant
peritoneal and pancreatic ascites [58,59], metastatic breast and
lung cancers [60,61], ovarian and melanoma tumors [56,61,62],
suggesting that metastatic cancer cells rely on VEGF-dependent
mechanisms in order to cross the endothelial barrier.
In order to examine the impact of cell-derived VEGF in the
process of melanoma and melanocyte extravasation across
endothelial monolayers, we characterized VEGF secretion by the
cells used in the present study, and sought to correlate this trait
with their ability to transmigrate. We observed a sustained VEGF
secretion by MV3 melanoma cells over time, while the normal
melanocyte cells (non-malignant) lineage barely produced this
growth factor, a fact that well correlated with their respective skills
to cross established endothelial monolayers in vitro, suggesting
that the pronounced metastatic potential of MV3 could be related
to an improved ability to secrete VEGF. Chen and colleagues [63]
showed that ATL-1 was able to inhibit the production of VEGF by
mouse hepatocarcinoma cells (H22). However, in our model, such
an inhibition by ATL-1 did not occur.
Several previous works by our group and by others have
demonstrated important anti-angiogenic properties of ATL analogs
[25–28]. Although VEGF has been extensively characterized both
as permeability and angiogenic factor – a fact that prompted it to
be named as VPF, from Vascular Permeability Factor – empiric
evidences suggest that the signaling pathways involved in
angiogenesis and endothelial barrier regulation can be eventually
independent from each other. For example, it has been shown that
mice deﬁcient in Scr or Yes small kinases do not exhibit vascular
leak response to VEGF, but show a normal angiogenic response
[64]. Therefore, studies to address the anti-metastatic potential of
lipoxin analogs, in particular their effects on crucial cellular steps
of intravasation and/or extravasation of tumor cells during
hematogenous cancer spread, are greatly warranted and presently
scarce in cancer cell literature.
Overall, the results presented herein suggest that the antago-
nizing effect of ATL-1 on VEGFR-2-dependent signaling, already
demonstrated as the basis for the anti-angiogenic properties of this
synthetic analog, may also imply a relevant anti-metastatic
potential of this molecule, a hypothesis that we intend to explore
in vivo, in the next steps of this work.
Fig. 7. Effect of ATL-1 on the short-term migration (4 h) of melanoma cells and melanocytes across endothelial monolayers, in response to exogenous VEGF addition. HUVEC
(5  104) were cultured in porous inserts (8 mm) and pretreated or not with ATL-1 (100 nM) for 30 min before incubation with or without VEGF (10 ng/mL) for 1 h. After the
treatment, MV3 cells (3  104) (A) or NGM cells (3  104) (B) previously labeled with PKH126 vital ﬂuorescent dye were incubated with endothelial monolayers for 4 h.
Migrating tumor cells were counted in a ﬂuorescence microscope. Values represent mean and standard deviation of three similar and independent experiments. *P < 0.05
VEGF versus all the other groups; **P < 0.05 for VEGF versus control and ATL1 + VEGF groups; #P < 0.05 for ATL-1 + VEGF versus control.
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